Business
Appointment of Nominated Advisor and Broker
Appointment of Nominated Advisor and Broker.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 9505C Avacta Group PLC 23 April 2013 \n \n\n \n \n\n\n\n\nPress Release\n\n\n23 April 2013\n\n\n\n\n \nAvacta Group plc\n(\"Avacta\" or \"the Group\")\n \nAppointment of Nominated Advisor and Broker\n \nAvacta Group plc (AIM:AVCT), a global provider of innovative diagnostic tools, consumables and reagents aimed at reducing the cost of human and animal healthcare, is pleased to announce that Numis Securities Limited has been appointed as the Company's nominated adviser and broker with immediate effect.\n \n- Ends -\n \n \nFor further information please contact:\n\n\n\n\nAvacta Group plc\nAlastair Smith, Chief Executive Officer \nTim Sykes, Finance Director\n\n\nTel: +44 (0) 844 414 0452 www.avacta.com\n\n\n\n\nNominated Advisor and Broker\nNumis Securities \nMichael Meade / Freddie Barnfield - Nominated Adviser\nJames Black - Corporate Broking\n\n\nTel: +44 (0) 207 260 1000\nwww.numiscorp.com \n\n\n\n\nMedia Enquiries\nAbchurch Communications\nSarah Hollins / Adam Michael / Harriet Rae\[email protected]\n\n\nTel: +44 (0) 207 398 7718\nwww.abchurch-group.com \n\n\n\n\n \nNotes to Editors:\nAvacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. \nAvacta's products address one of the most significant global challenges facing mankind today - the rapidly rising cost of healthcare for a growing and ageing population.\n \nThe cost of healthcare is driven by many factors. New drugs are expensive to develop, most don't reach the patient and those that do are often very costly to prescribe. Inadequate, incorrect or slow diagnosis causes delays that lead to longer or less effective courses of treatment resulting in lengthy or repeated hospitalisation.\n \nAvacta is dedicated to developing and providing innovative and practical tools to help drug developers get their products to market quicker and more reliably, and to providing clinicians with rapid and powerful diagnostics to improve patient treatment, helping to reduce the cost of healthcare worldwide.\n \nAvacta joined AIM in August 2006 and is based in Wetherby, England.\n \nFor further information visit www.avacta.com \n \n\nThis information is ...